Seegene received US FDA Emergency Use Authorization for a multiplex real-time PCR assay designed to detect and differentiate herpes simplex virus 1/2, varicella-zoster virus, and mpox from ulcerative skin lesions. The Allplex HSV-1&2/VZV/MPXV assay is meant to reduce diagnostic misses when clinicians test one pathogen at a time based on lesion appearance. Seegene said it used its proprietary high-multiplex PCR technologies and digitalized development system to build the test, and framed the EUA as a step toward expanding locally relevant multiplex diagnostics for US laboratories and public health needs. In practice, this is a near-term regulatory win for multiplex molecular diagnostics, aligning with ongoing demand for rapid differential testing in outbreak-prone and clinically overlapping presentations.